SAM
RLMD icon

Smartleaf Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Smartleaf Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35
Closed -$104 – 2971
2024
Q2 		$104 Buy
+35
New +$127 ﹤0.01% 2721

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Smartleaf Asset Management's RLMD Position: Q3 2024 in Review

Smartleaf Asset Management sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 35 shares — an estimated $104 sold.

Smartleaf Asset Management first reported a position in RLMD in Q2 2024 and held it in 1 quarter. The position peaked at $104 in Q2 2024. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Smartleaf Asset Management reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 35 Relmada Therapeutics shares in Q3 2024, an estimated $104.
  • Smartleaf Asset Management first reported a position in Relmada Therapeutics in Q2 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Relmada Therapeutics position peaked at $104 in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Smartleaf Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.